|CNAT -- USA Stock|| |
USD 5.42 0.05 0.93%
CFO, Senior Vice President of Finance, Secretary
Mr. Charles J. Cashion is Chief Financial Officer, Senior Vice President of Finance, Secretary of Conatus Pharmaceuticals Inc., since July 2005. From 2001 to 2005, he was Chief Financial Officer at Idun. He has held several senior level management positions in both private and public healthcare companies with responsibilities for securing and executing various types of financings including initial public offerings, secondary offerings, corporate partnerships, and debt. He has also been involved with the strategic planning, acquisition and integration of several technology companies. He joined Idun Pharmaceuticals in 2001 as Executive Vice President, Chief Financial Officer and Secretary. Previously, he held the position of Senior Vice President and Chief Financial Officer of Quidel Corporationrationration, a publiclyheld medical diagnostics company. For the prior nine years, he was Senior Vice President, Finance, and Chief Financial Officer of The Immune Response Corporationrationration, a publiclyheld biopharmaceutical company. During the period from 1980 to 1989, he was Executive Vice President and Chief Financial Officer of Smith Laboratories, Inc., a publiclyheld pharmaceutical company and during 1987 through 1989 was also President and Chief Executive Officer of Sutter Corporationrationration, an orthopedic products subsidiary of Smith Laboratories. He also held positions at Baxter International, Inc. and Motorola, Inc. He serves on the boards of directors of NovaBay Pharmaceuticals, Inc., Ridge Diagnostics, Inc., La Jolla Institute for Allergy Immunology, and iDiverse, Inc
Age: 64 President Since 2005 MBA
Cashion holds an M.B.A. and B.S. in Accounting from Northern Illinois University.
The company has return on total asset (ROA)
of (14.76) %
which means that it has lost $14.76 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (87.78) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 13.34 M in liabilities with Debt to Equity (D/E) ratio of 57.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals has Current Ratio of 2.36 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. The company was founded in 2005 and is headquartered in San Diego, California. Conatus Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 33 people.Conatus Pharmaceuticals (CNAT) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 33 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Conatus Pharmaceuticals Leadership Team
|Edward Smith, President, MBA|
|Michelle Vandertie, Executive|
|Dan Kisner, Director|
|James Scopa, Director|
|Steven Mento, CEO|
|Daniel Kisner, Director|
|Preston Klassen, Director|
|David Hale, Chairman|
|Harold Wart, Director, Ph.D|
|William LaRue, Director, MBA|
|Alfred Spada, Founder, Ph.D|
|Charles Cashion, President, MBA|
|Daniel Ripley, President, MBA|
|Keith Marshall, President, MBA|
|Louis Lacasse, Director, MBA|
|Shahzad Malik, Director|
|David Hagerty, President|
Stock Performance Indicators
Most of Macroaxis users are currently bullish on Conatus Pharmaceuticals. What is your opinion about investing in Conatus Pharmaceuticals? Are you bullish or bearish?
and pair trading evaluation for Conatus Pharmaceuticals and NantKwest
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return